Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 40 years old~2. Diagnosis of Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL)~3. Candidates for HDT-AHCT with one of the following conditioning regimens:~   1. BEAM (carmustine, etoposide, cytarabine, melphalan)~  2. BeEAM (bendamustine, etoposide, cytarabine, melphalan)~4. Achieved CR or PR prior to planned HDT~5. ECOG ≤ 2~6. Weight ≤ 1.6 × ideal body weight (IBW) per Devine formula~7. Serum bilirubin ≤ 2 mg/dL, unless benign congenital hyperbilirubinemia~8. AST, ALT, and alkaline phosphatase \< 3 × ULN~9. Creatinine clearance ≥ 30 ml/min (calculated by Cockcroft Gault)~10. LVEF ≥ 45% by MUGA or resting echocardiogram~11. Pulmonary function (FEV1 and corrected DLCO) ≥ 45% predicted~12. Willingness and ability to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, other study procedures, and study restrictions~13. Sexually active females of childbearing potential must have a negative urine pregnancy test and agree to use two accepted methods of contraception during the study and for 3 months after their last dose of study drug.~14. Male subjects who are sexually active and who are partners of females of childbearing potential: agreement to use two forms of contraception as in criterion 12 above and to not donate sperm during the treatment period and for at least 3 months after the last dose of study drug~15. Ability to provide written informed consent.~Exclusion Criteria:~1. History of prior HCT~2. Primary CNS lymphoma~3. Lymphoma with CNS involvement at time of relapse prior to planned HDT-AHCT~4. Active malignancy other than the one for which the subject is undergoing HDT AHCT. Subjects with cervical carcinoma in situ or localized basal or squamous cell carcinoma treated with definitive surgery are eligible~5. Subjects with a serious concomitant medical condition that could interfere with the conduct of the clinical trial, such as unstable angina, renal failure requiring hemodialysis, or active infection requiring IV antibiotics~6. Subjects with a known history of HIV~7. Subjects who have known hypersensitivity reactions to bovine (cow) proteins or documented allergy to DMSO~8. Subject has other conditions that in the opinion of the investigator would require reduced dose (intensity) of BEAM or BeEAM regimens

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AB-205 plus standard-of-care preventive and supportive therapies. (Type: EXPERIMENTAL): None
- Placebo plus standard-of-care preventive and supportive therapies. (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy